Article
Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jan 2017
Dieter S M, Heining C, Agaimy A, Huebschmann D, Bonekamp D, Hutter B, Ehrenberg K R, Fröhlich M, Schlesner M, Scholl C, Schlemmer H-P, Wolf S, Mavratzas A, Jung C S, Gröschel S, von Kalle C, Eils R, Brors B, Penzel R, Kriegsmann M, Reuss D E, Schirmacher P, Stenzinger A, Federspil P A, Weichert W, Glimm H, Fröhling S
Abstract excerpt
Background: Sinonasal carcinomas (SNCs) comprise various rare tumor types that are characterized by marked histologic diversity and largely unknown molecular profiles, yet share an overall poor prognosis owing to an aggressive clinical course and frequent late-stage diagnosis. The lack of effective systemic therapies for locally advanced or metastatic SNC poses a major challenge to therapeutic decision making for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.